Amplify Treatments, Testing and Advancements ETFNYSE Arca:GERM
- LAST PRICE18.40
- TODAY'S CHANGE (%)0.25 (1.39%)
- Bid / Lots0.00/ 0
- Ask / Lots18.50/ 3
- Open / Previous Close18.29 / 18.14
- Day Range
- 52 Week Range
- Volume323
- Overall Morningstar Rating1 out of 5 Starsout of 265 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GERM |
|---|---|---|
| 12:38 ET | 144 | 18.2854 |
| 03:59 ET | 0 | 18.3951 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 02/20/2024 | -1.30% |
| 02/21/2024 | -0.84% |
| 02/22/2024 | -1.17% |
| 02/23/2024 | -0.08% |
| 02/26/2024 | -0.28% |
| 02/27/2024 | -0.44% |
| 02/28/2024 | -0.38% |
| 02/29/2024 | 0.03% |
| 03/01/2024 | 0.05% |
| 03/04/2024 | -0.97% |
| 03/05/2024 | -0.83% |
| 03/06/2024 | -0.14% |
| 03/08/2024 | -0.74% |
| 03/11/2024 | -0.48% |
| 03/12/2024 | -0.04% |
| 03/13/2024 | -0.05% |
| 03/14/2024 | -0.06% |
| 03/15/2024 | -0.26% |
| 03/18/2024 | 0.01% |
| 03/19/2024 | -0.29% |
| 03/20/2024 | -0.94% |
| 03/21/2024 Largest Discount | -1.66% |
| 03/22/2024 | -1.25% |
| 03/25/2024 | -0.41% |
| 03/26/2024 | -0.19% |
| 03/27/2024 | -0.24% |
| 03/28/2024 | -0.50% |
| 04/01/2024 | -0.18% |
| 04/02/2024 | -0.23% |
| 04/03/2024 | -0.15% |
| 04/04/2024 Largest Premium | 0.80% |
| 04/05/2024 | -0.19% |
| 04/09/2024 | -1.33% |
| 04/10/2024 | -0.54% |
| 04/11/2024 | -0.58% |
| 04/15/2024 | -1.34% |
| 04/16/2024 | -0.32% |
| 04/17/2024 | -0.51% |
| 04/18/2024 | 0.72% |
| 04/19/2024 | -1.01% |
| 04/22/2024 | -0.09% |
| 04/23/2024 | -0.52% |
| 04/24/2024 | -0.52% |
| 04/25/2024 | -0.30% |
| 04/26/2024 | -0.55% |
| 04/29/2024 | -0.37% |
| 04/30/2024 | 0.04% |
| 05/01/2024 | 0.08% |
| 05/02/2024 | -0.01% |
| US Stock | 80.9% |
|---|---|
| Non-US Stock | 18.5% |
| Cash | 0.6% |
| Convertible | 0 |
| Non-US Bond | 0 |
| Other | 0 |
| Healthcare | 99.4% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 81.4% |
|---|---|
| Europe | 8.9% |
| Asia/Oceania | 0.8% |
| Africa | 0 |
| Latin America | 0 |
| Canada | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Moderna Inc | Long | 7.6% | 0.00% | $721.4K |
ImmunityBio Inc Ordinary Shares | Long | 7.1% | 0.00% | $679.3K |
Quest Diagnostics Inc | Long | 7.0% | 0.00% | $667.4K |
BioNTech SE ADR | Long | 6.3% | 0.00% | $602.3K |
Alnylam Pharmaceuticals Inc | Long | 6.0% | 0.00% | $574.6K |
Laboratory Corp of America Holdings | Long | 5.9% | 0.00% | $562.8K |
QuidelOrtho Corp | Long | 3.8% | 0.00% | $357.6K |
Immunocore Holdings PLC ADR | Long | 3.7% | 0.00% | $353.5K |
Dynavax Technologies Corp | Long | 3.7% | 0.00% | $351.2K |
Bio-Rad Laboratories Inc Class A | Long | 3.5% | 0.00% | $332.9K |
Reports
- ManagedInvestmentETF04/07/24
Morningstar ETF Report
The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | 1 out of 5 Stars |
| 3 Year Rating | 1 out of 5 Stars |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | Prime Treatm, Testing and Adv TR USD |
|---|---|
Category | |
Sponsor | Amplify Investments LLC |
Inception | June 17, 2020 |
The investment seeks investment results that generally correlate to the total return performance of the Prime Treatments, Testing and Advancements Index. Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.
| Total Net Assets | $9.5M |
|---|---|
| Shares Out. | 550.0K |
| Net Asset Value (NAV) | $18.14 |
| Prem/Discount to NAV | -0.01% |
| P/E Ratio | --- |
| Dividend Yield | 1.13% |
| Dividend per Share | 0.21 USD |
| Ex-Dividend Date | 03/26/2024 |
| Dividend Payment Date | 03/28/2024 |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Small Cap Blend |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.68% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | --- |